Company Overview
BIOCRYST PHARMACEUTICALS INC
BCRXRevenue vs. Cost of Revenue
Revenue
Cost of Revenue
Total Operating Expenses vs. Operating Income
Total Operating Expenses
Operating Income
Net Income
Net Income
Revenue
—M
2025 FY
Net Income
264M
2025 FY
Shares Outstanding
210M
2025 FY
EPS
1.26USD
2025 FY
Company Information
SIC Code
2836
CIK Code
882796
Exchange
Nasdaq
Location
US